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Abstract
Background: Chlamydophila pneumoniae infection has been implicated as a potential risk factor for
atherosclerosis, however the mechanism leading to persistent infection and its role in the disease
process remains to be elucidated.
Methods: We validated the use of tissue microarray (TMA) technology, in combination with
immunohistochemistry (IHC), to test antibodies (GroEL, GroES, GspD, Ndk and Pyk) raised
against differentially expressed proteins under an interferon-gamma (IFN-γ) induced model of
chlamydial persistence.
Results: In the cell pellet array, we were able to identify differences in protein expression patterns
between untreated and IFN-γ treated samples. Typical, large chlamydial inclusions could be
observed in the untreated samples with all antibodies, whereas the number of inclusions were
decreased and were smaller and atypical in shape in the IFN-γ treated samples. The staining results
obtained with the TMA method were generally similar to the changes observed between normal
and IFN-γ persistence using proteomic analysis. Subsequently, it was shown in a second TMA
including archival atheromatous heart tissues from 12 patients undergoing heart transplantation,
that GroEL, GroES, GspD and Pyk were expressed in atheromatous heart tissue specimens as well,
and were detectable morphologically within lesions by IHC.
Conclusion: TMA technology proved useful in documenting functional proteomics data with the
morphologic distribution of GroEL, GroES, GspD, Ndk and Pyk within formalin-fixed, paraffin-
embedded cell pellets and tissues from patients with severe coronary atherosclerosis. The
antibodies GroEL and GroES, which were upregulated under persistence in proteomic analysis,
displayed positive reaction in atheromatous heart tissue from 10 out of 12 patients. These may be
useful markers for the detection of persistent infection in vitro and in vivo.
Published: 19 October 2006
BMC Infectious Diseases 2006, 6:152 doi:10.1186/1471-2334-6-152
Received: 01 June 2006
Accepted: 19 October 2006
This article is available from: http://www.biomedcentral.com/1471-2334/6/152
© 2006 Borel et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2006, 6:152 http://www.biomedcentral.com/1471-2334/6/152
Page 2 of 8
(page number not for citation purposes)
Background
Chlamydophila (C.) pneumoniae is an obligate intracellular
pathogen which causes both acute and chronic respiratory
infections in humans [1-5]. Over the last decade, several
reports in the literature have suggested that infection with
C. pneumoniae may also contribute to the pathogenesis of
atherosclerosis [6,7]. C. pneumoniae was detected in
atheromatous lesions by isolation in pure culture,
polymerase chain reaction (PCR), electron microscopy, in
situ hybridization (ISH) and immunohistochemistry
(IHC) [8-11]. In order to play a causative role in chronic
diseases,  C. pneumoniae would need to persist within
infected tissue for extended periods of time, thereby stim-
ulating a chronic inflammatory response.
In vitro, an alteration of the normal developmental cycle
of C. pneumoniae can be induced by interferon-γ-mediated
induction of the host cell indoleamine 2,3-dioxygenase
(IDO) activity, leading to a persistent form of the organ-
ism [12-15]. In addition, several other models of in vitro
persistence have been described (i.e. iron-limitation and
antibiotics) [16]. Nevertheless, it is unknown which genes
and proteins of C. pneumoniae are involved in the develop-
ment and maintenance of persistence. We have previously
characterized an IFN-γ induced model of persistence by
2D gel electrophoresis [17-19], and identified several pro-
teins that are differentially regulated during the induction
of persistence.
Tissue microarray (TMA) technology, developed by
Kononen et al., 1998 [20] represents a promising
approach in the field of proteomics for its potential use-
fulness in in situ analysis. Preparations for TMA are con-
structed by obtaining cylindrical tissue specimens from
paraffin blocks, assembling several hundreds into a single
block, and preparing sections containing multiple tissue
specimens [20-22]. TMA sections can be analyzed using
standard pathology methods, such as hematoxylin and
eosin (HE) staining or special stains and in situ analyses,
such as immunohistochemistry (IHC) [20,21,23-25]. The
utility of TMA protocols for high-throughput expression
profiling of tumors at the molecular and protein levels has
been widely used in human cancer research on formalin-
fixed and paraffin-embedded biopsy specimens
[20,21,26,27].
Since many markers of gene and protein expression are
first established and studied in cell culture systems, it is
useful to include cultured cells in TMAs for preliminary
studies when translating experimental techniques from
laboratory systems to studies of human tissue. Therefore,
in the present study, we used 5 polyclonal antibodies
directed against differentially regulated chlamydial pro-
teins during in vitro persistence [18,19] to validate the use
of TMA technology on non-persistently, persistently
infected and uninfected HEp-2 cell pellets. In addition,
archival atheromatous heart tissues [10] were tested by
TMA, in combination with IHC, using the same antibod-
ies, to determine their potential future use in detecting
persistently infected tissue.
Methods
Cell line
HEp-2 cells (ATCC CCL-23) were obtained from the
American Type Culture Collection (Rockville, MD) and
maintained in Iscove's Maintenance Medium (IMM)
(Cellgro, Washington, DC), as described previously [28].
Bacterial isolate
C. pneumoniae A-03 (ATCC VR-1452), previously isolated
from an atheroma of a patient with coronary artery dis-
ease during heart transplantation at the Jewish Hospital
Heart and Lung Institute, Louisville, KY [10], were propa-
gated in HEp-2 cell monolayers in Iscove's Growth
Medium (IGM), as described previously [28]. Elementary
bodies (EBs) were harvested and purified by disruption of
HEp-2 cell monolayers with a cell scraper, sonication and
centrifugation over a renografin density gradient [28]. EB
suspensions were stored in sucrose-phosphate-glutamic
acid buffer at -80°C, after which viable titers were estab-
lished using standard methods.
Patients specimens
Archival atheromatous tissue specimens from twelve
patients undergoing heart transplantation were investi-
gated. Results from culture, PCR, IHC, ISH, EM and serol-
ogy testing have been described previously [10]. The study
of Ramirez et al. was approved by the Institutional Review
Boards (IRB) at both the University of Louisville and Jew-
ish Hospital Healthcare Corporation.
Preparation of antibodies
Five proteins were identified as being differentially regu-
lated in the IFN-γ-induced model of persistence [17,19]:
(i) GroEL (60 kDa chaperonin) and (ii) GroES (10 kDa
chaperonin) are both chaperons involved in protein fold-
ing, assembly and modification, (iii) GspD (general secre-
tion protein D) involved in general protein secretion, (iv)
Ndk (nucleoside-2-phosphate-kinase) involved in base
and nucleotide metabolism of amino acid biosynthesis,
and (v) Pyk (pyruvate kinase) involved in the energy
metabolism (glycolysis and gluconeogenesis). GroEL was
analysed and quantitated previously [17], and the remain-
ing four proteins were selected and confirmed in an iden-
tical fashion [19]. GroEL and GroES were upregulated
under persistence, whereas GspD and Pyk remained
unchanged and Ndk was downregulated. Each protein
was plugged from a silver-stained 2D gel, which was
obtained from a purified EB preparation [18,19,28], and
used for antibody production of polyclonal antibodies atBMC Infectious Diseases 2006, 6:152 http://www.biomedcentral.com/1471-2334/6/152
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Harlan Bioproducts for Science, Inc. (Indianapolis, IN,
USA). Pathogen-free, barrier-raised New Zealand white
rabbits were immunized four times with the antigens, and
sera from the final bleed were used in this study. The spe-
cificity of each antibody was confirmed in our laboratory
by 2D gel electrophoresis of a purified C. pneumoniae EB
preparation followed by western blot analysis, demon-
strating specific reactivity on the blot which corresponded
to the molecular weight and iso-electric point of each
individual protein (data not shown).
Other antibodies used
The following antibodies were also used in these studies.
(i) Chlamydiaceae family-specific mouse monoclonal anti-
body directed against the chlamydial lipopolysaccharide
(mLPS; Clone ACI-P, Progen, Heidelberg, Germany).
(ii) Chlamydiaceae family-specific rabbit polyclonal anti-
body directed against both the chlamydial LPS and the
chlamydial major outer membrane protein (MOMP)
(pLPS/MOMP; Cygnus Technologies, Inc., Southport,
NC).
TMA analysis
Infection protocol
HEp-2 cells were grown in 75-cm2 cell culture flasks (Cos-
tar, Cambridge, MA) to confluency and inoculated with
purified C. pneumoniae EB (1 × 109 IFUs/flask) in IGM
with or without human recombinant IFN-γ (50 and 100 U
per ml), followed by centrifugation at 675 × g (Sorvall TR
6000D) for 30 min at 10°C and incubating at 37°C in 5%
CO2 for 24, 48 and 72 hpi. After the respective incubation
period, the medium was aspirated and the monolayers
were washed twice with 1 × phosphate buffer saline (PBS).
Monolayers were fixed with 4% formalin in 1 × PBS for 10
min followed by two washes with 1 × PBS. All monolayers
were harvested from the flasks with a cell scraper and
transferred into 15 ml of 1 × PBS. After centrifugation at
675 × g for 10 min at 20°C, the supernatant was dis-
carded. The pellets were re-suspended in 5% BSA prepared
in 1 × PBS and transferred to an Eppendorf™ tube (Eppen-
dorf-Netheler-Hinz GmbH, Hamburg, Germany) with
one drop of hematoxylin for visualization. The cell sus-
pensions were centrifuged for 5 min at 950 × g and the
supernatant was discarded. The resulting pellets were then
embedded in paraffin using the Cytoblock™ cell block
preparation system (Shandon™, Pittsburg, USA). For each
condition (timepoints 24, 48 and 72 h, concentrations of
50 U/ml and 100 U/ml of IFN-γ) four sets of infected
monolayers were prepared. As controls, four sets of unin-
fected HEp-2 monolayers without and with 100 U/ml
IFN-γ, were prepared as pellets.
TMA setup
Two equal cell culture array blocks including four equal
prepared sets of cell pellets were created with the TMA
Builder from Histopathology Ltd., Hungary according to
the instructions of the manufacturer. Briefly, the recipient
paraffin block with 24 holes of diameter 2 mm each
arranged in four columns and six rows was moulded with
the TMA Builder. The whole cell pellets from the donor
blocks were punched out with the Paraffin-Punch-Extrac-
tor and were arrayed in the preformed recipient paraffin
block according to protocol.
Formalin-fixed and paraffin-embedded coronary artery
specimens were available from the 12 patients (1 to 7 par-
affin blocks per patient). Three TMA blocks including
each tissue of the 12 patients, an uninfected and an
infected control HEp-2 cell pellet (72 hpi, without IFN-γ)
were created in an identical fashion. 4 μm slide were cut
using a standard microtome.
Immunohistochemistry
Paraffin sections were stained with the following primary
anti-chlamydial-antibodies: (1) mLPS at a dilution of
1:50, (2) pLPS/MOMP at a dilution of 1:400, (3) GroEL,
GroES, GspD, Ndk and Pyk at a dilution of 1:200. These
optimal dilutions were previously determined. Detection
was performed with the Detection Kit (Dako ChemMate™
Detection Kit, Glostrup, Denmark) according to the man-
ufacturer's instructions. Antigen retrieval was performed
by one min enzyme digestion (Pronase) (mLPS and pLPS/
MOMP) and microwave heating (750 W for 10 minutes)
two times in citrate buffer (pH 6,0; Target Retrieval Solu-
tion (× 10), Dako ChemMate™, Glostrup, Denmark)
(GroEL, GroES, GspD, Ndk and Pyk), respectively. For
inhibition of the endogenous peroxidase activity, the
slides were immersed in peroxidase-blocking solution
(Dako ChemMate™, Glostrup, Denmark) for 5 min at
room temperature (RT). Two additional blocking solu-
tions were added to the slides, which were incubated with
the polyclonal antibodies GroEL, GroES, GspD, Ndk and
Pyk: Dako Protein Block Serum-free for 5 min at room
temperature (Dako ChemMate™, Glostrup, Denmark)
and 20 min Avidin D solution followed by 20 min Biotin
solution at room temperature (Vector). The slides were
incubated with the primary antibody for 60 min (mLPS
and pLPS/MOMP) or over night (GroEL, GroES, GspD,
Ndk and Pyk) at room temperature in a moist chamber. In
total, the IHC for each antibody was repeated at least four
times on consecutive sections.
Results
Cell pellet array
Results with the monoclonal antibody directed against
LPS (mLPS) and the polyclonal antibody directed against
chlamydial LPS and MOMP (pLPS/MOMP) were similar.BMC Infectious Diseases 2006, 6:152 http://www.biomedcentral.com/1471-2334/6/152
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Typical large, uniformly-staining chlamydial inclusions,
located near the host cell nucleus, could be seen at 48 and
72 hpi in the untreated samples with the mLPS (Figure 1)
and the pLPS/MOMP antibody. Results with the 5 poly-
clonal antisera tested, showed similar staining patterns in
the untreated samples, however, not all inclusions were
stained uniformly positive (Figure 1). Earlier in the
chlamydial developmental cycle at 24 h, granular positive
material was seen in the cytoplasm of untreated cell pel-
lets with the mLPS antibody and the pLPS/MOMP anti-
body, as well as the GroEL, GroES and Pyk antibodies, and
to a lesser extent, with the GspD (data not shown). All pel-
lets at 24 hpi were negative with the Ndk antibody.
The IFN-γ-treated samples displayed an overall decrease in
positive reactivity. At 48 and 72 hpi, the number of inclu-
sions were decreased and were obviously smaller and
atypical in morphology (Figure 1). This could be observed
for all antibodies, except for Ndk, which was negative in
all IFN-γ-treated samples (Figure 1). There was no differ-
ence in inclusion morphology and antibody staining pat-
terns seen between the two concentrations of IFN-γ (50 U/
ml or 100 U/ml). Overall, the assay showed good repro-
ducibility in all four replicates of monolayers.
TMA with atheromatous heart tissues
Granular, positive-staining material was seen in the cyto-
plasm of subintimal macrophages and smooth muscle
cells in the medial part of the affected coronary arteries of
all patients with at least one antibody, except the two
patients with negative results for the presence of C. pneu-
moniae in the original study (patients # 7 and 11) [10].
Patients # 10 and 12 were positive with all antibodies
used except of the Ndk, which was negative in all 12 heart
tissue specimens. Patients # 1, 2, 3 and 9 were positive
with the GroEL, GroES, GspD and Pyk, whereas patients #
4 and 6 were only positive with the GroEL, GspD and Pyk.
Patient # 5 was positive with the GroES and Pyk, and
patient # 8 revealed positive reaction with the GroEL and
GspD. All patients were negative when tested with the
mLPS, whereas the pLPS/MOMP ab revealed positive reac-
tions in patients # 10 and 12.
Positive staining of the antibodies GroEL and GroES in
patient # 10 and GspD and Pyk in patient # 12, respec-
tively, is displayed in figure 2.
Discussion
In this study, TMA technology was useful in documenting
functional proteomics data showing the morphologic dis-
tribution of GroEL, GroES, GspD, Ndk and Pyk within for-
malin-fixed, paraffin-embedded cell pellets and
atheromatous heart tissues. GroEL, GroES, GspD, Ndk
and Pyk, selected as differentially regulated proteins from
proteomic analysis, were expressed in C. pneumoniae-
infected, untreated and IFN-γ treated HEp-2 cells and
atheromatous heart tissues and were detectable morpho-
logically by IHC. In general, IHC allows the detection of
the presence of an antigen in tissue sections, however, the
intensity of antigen labelling does not correlate with the
amount of antigen present. The IHC labelling evaluated in
this study, therefore, represents the presence or absence of
proteins, but does not reflect quantitative expression of
GroEL, GroES, GspD, Ndk, Pyk, mLPS and/or pLPS/
MOMP.
By using cell pellet array, in combination with IHC, it was
possible to identify the number, size and morphology of
the chlamydial inclusions. Numbers of inclusions at 48
hpi and 72 hpi were decreased under IFN-γ-persistence
and the inclusions were smaller and atypical, as described
previously [15], however, the staining intensity remained
the same as that seen in untreated cells.
The staining results obtained with the TMA method were
generally similar to the changes observed between normal
and IFN-γ persistence using proteomic analysis [17-19].
For example, GroEL, which was upregulated in proteomic
analysis, displayed more positive reactions in the IFN-γ
treated samples when compared to GspD, which
remained unchanged in the proteomic analysis. Likewise,
Ndk reactivity remained negative in all IFN-γ-treated sam-
ples by TMA, which corresponded to the downregulation
observed in the proteomic analysis.
In comparison to other methods, such as PCR, we were
able to localize and visualize the positive reactions within
the atheromatous heart tissue by TMA, in combination
with IHC. The TMA method allowed a comparison
between multiple cell pellets or tissue specimens on one
microscope slide. The 2 mm punch, in combination with
the Tissue Microarray Builder allowed easy manipulation
during punching, facilitating a rapid preparation of the
cell culture array block. The fact that the 2 mm punch can
cause significant damage to the donor block was not of
importance because each donor block contained only one
single cell pellet that was entirely punched out and the
whole area of each pellet could be examined. Other punch
sizes such as 0.6 mm and 1.2 mm cause less damage to the
original donor block and make it possible to array several
hundreds of specimens on one single block, however the
creation of this block is more laborious. The problem of
reduction of the amount of tissue analyzed from the
whole cell pellet to a disk, which may be not be represent-
ative of the protein expression of the entire tissue speci-
men, can be solved by performing the experiments in
several-fold redundancy. For that reason, we created two
equal cell pellet blocks including four sets of equally pre-
pared monolayers containing the three timepoints
(treated and untreated cell pellets and negative controls).BMC Infectious Diseases 2006, 6:152 http://www.biomedcentral.com/1471-2334/6/152
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cell pellet array Figure 1
cell pellet array. Photomicrographs of TMA preparations of whole cell pellets showing differential expression pattern of C. 
pneumoniae proteins under untreated (A) and 50 U/ml IFN-γ treated (B) conditions at 48 hpi. Representative monolayers are 
shown to depict distinct differences in morphology and size of inclusions, as they were smaller and atypical under IFN-γ-
induced persistence in comparison to the untreated monolayers.BMC Infectious Diseases 2006, 6:152 http://www.biomedcentral.com/1471-2334/6/152
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Multiple sections of the two TMA blocks were cut and
probed with each antibody.
Multiple sections of 3 TMA blocks, including the athero-
matous heart tissue, were investigated with each antibody.
In our previous study, patients # 1, 2, 3, 6 and 12 were
positive by IHC using Chlamydia-specific and C. pneumo-
niae-specific antibodies [10]. We were able to detect 5
more positive patients with experimentally produced anti-
GroEL, anti-GroES, anti-GspD and anti-Pyk antibodies.
Thus, differentially regulated proteins by proteomic anal-
ysis were expressed in C. pneumoniae-infected human
atheromatous heart tissue specimens and were detectable
morphologically within lesions by IHC. The staining
results obtained with the TMA corresponded to the reac-
tivity as determined by proteomic analysis, for example,
GroEL and GroES, which were upregulated under persist-
ence in proteomic analysis, were likewise positive in most
heart tissue specimens. Patients # 7 and 11, which under-
went heart transplantation primarily due to myocarditis,
rather than severe atherosclerosis (unpublished data), dis-
played questionable positive results (GroEL, GroES, GspD
and Pyk). As these 2 patients were in fifth decade of life
and had elevated anti-C. pneumoniae titers in the microim-
TMA with atheromatous heart tissues Figure 2
TMA with atheromatous heart tissues. Photomicrographs of TMA preparations of atheromatous heart tissues of patient 
# 10 showing positive reaction within macrophages with GroEL (1) and with GroES (2) and in patient # 12 showing positive 
reaction within smooth muscle cells with GspD (3) and Pyk (4).BMC Infectious Diseases 2006, 6:152 http://www.biomedcentral.com/1471-2334/6/152
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munofluorescence assay [10], we tend to assume that they
suffered from atherosclerosis and were Chlamydia-
infected as patients # 1–6, 10 and 12, but perhaps to a
lesser extent. Definitive demonstration of chlamydial par-
ticles in patients # 7 and 11 by more sensitive techniques
(i.e. ultrastructural studies) is in progress [29].
Conclusion
Overall, GroEL and GroES tend to be useful markers to
detect persistent infection in vitro and in vivo. In addition,
GspD and Pyk antibodies gave similar reactivity, indicat-
ing appropriate sensitivity and specificity, and may also
allow the detection of C. pneumoniae in chronically-
infected tissue. Antibody prepared against Ndk remained
negative in tissue specimens from all 12 archived athero-
matous tissue specimens, which corresponded nicely to
the downregulation observed in proteomic analysis.
These data represent the first thorough examination of
atheromatous tissue by experimentally produced antibod-
ies against C. pneumoniae and may provide a useful tech-
nique to further define the role of this organism in
atherosclerosis and other chronic human diseases.
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